Leonard Keith R 4

4 · Arcutis Biotherapeutics, Inc. · Filed Mar 4, 2026

Form 4

Period: 2026-03-02

Director

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-03-02$8.63/sh+27,052$233,459→ 49,175 total
Exercise/Conversion
Common Stock
[F1]
2026-03-02$7.51/sh+12,220$91,772→ 61,395 total
Sale
Common Stock
[F1][F2]
2026-03-02$25.39/sh−39,272$997,195→ 22,123 total
Exercise/Conversion
Stock Option (right to buy)
[F1][F4]
2026-03-02−27,052→ 0 total
Exercise: $8.63Exp: 2034-06-14→ Common Stock (27,052 underlying)
Exercise/Conversion
Stock Option (right to buy)
[F1][F4]
2026-03-02−12,220→ 0 total
Exercise: $7.51Exp: 2033-05-31→ Common Stock (12,220 underlying)

Holdings

Footnotes (4)

[F1]The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on November 18, 2025, by the Reporting Person, with a plan end date of February 16, 2027.
[F2]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.05 to $26.039, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
[F3]Shares held by Leonard Family Trust dated August 28, 1996, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
[F4]The option is fully vested.

Signature

/s/ Latha Vairavan, as Attorney-in-Fact for Keith Leonard|2026-03-04

Documents

1 file